Surgery in the management of XXXX .

@entity1 @entity151 @entity189
OBJECTIVE: We analyzed our experience in the period January 1975-December 1995 aiming to confirm the role of surgery in the multimodality treatment of @entity151 ( @entity151 ). METHODS: 127 @entity1 (5.28% of the overall lung resections for @entity189 ) underwent surgery for @entity151 . The median age was 60 years (range 34-73). In 87 @entity1 (68.5%) a pre-operative tissue diagnosis was effected and those @entity1 underwent a complete staging procedure. Fifteen @entity1 received up to six complete courses of neoadjuvant and adjuvant chemotherapy. The surgical procedures included: 50 pneumonectomies, 71 lobectomies and six wedge resections. Two @entity1 experienced a local recurrence and a completion pneumonectomy was performed. RESULTS: The median follow-up is 66 months (range 6-214). The 5-year actuarial survival rate is 22.6% (median 18 months). Twenty-three @entity1 are still alive, 21 of them being disease-free. Considering the most conspicuous group of @entity1 (n = 92) treated by surgery and adjuvant chemotherapy, the survival data were 47.2, 14.8 and 14.4% for Stage I, II and III, respectively (P = 0.001). NO @entity1 had a significantly better survival than N1 and N2 @entity1 (P = 0.035). CONCLUSIONS: Surgery and adjuvant chemotherapy might represent an effective form of treatment of limited @entity151 without lymph-node involvement. The role of surgery is yet to be verified as regards N1 and N2 status, where even neoadjuvant chemotherapy has not achieved the hoped-for results (no @entity1 reaching a 2-year survival).
